Pharmaceutics
International, Inc.
10819 Gilroy Road
Hunt Valley, MD 21031
410-584-0001
Fax: 410-584-0007
Business Development
| Dr.
David Goldman Dr. David Goldman is the Vice President of Scientific Affairs and Formulation Development at PII, a company that focuses on the development of formulations and delivery systems for solid, liquid, and semi-solid dosage pharmaceutical products. Bringing
to PII over 24 years of pharmaceutical experience with a focus
on development activities related to commercialization of
new molecular entities (NMEs), David also has a thorough knowledge
of biopharmaceutic and physicochemical properties that influence
absorption and bioavailability. During his career, David has
been instrumental in overcoming ADME related issues for drugs
in development through approaches that are focused on the
improvement of drug properties while also building extensive
experience with bench scale development to full scale commercial
manufacturing and associated regulatory activities. After receiving
a B.S. in Pharmacy from Idaho State University, David obtained
a Ph. D in Medicinal Chemistry from SUNYAB where he held the
position of AFPE doctoral fellow. With a technical background
and experience in analytical chemistry, organic chemistry,
pharmaceutics, drug delivery and process development, Dr.
Goldman is named an inventor on 6 patents or pending applications
addressing drug delivery and has published 10 scientific manuscripts
and given more than 27 scientific presentations. Prior to
PII, Dr. Goldman developed a wide range of drug dosage forms
while working for three major pharmaceutical companies, including
Wyeth, Hoffmann – La Roche, and Bayer Pharmaceuticals. Starting
in Pharmacy R&D, David was a group leader supporting new product
introductions and technical services conducting commercial
scale-up, troubleshooting, and process optimization and validation
projects. As development team leader and section head of Pharmacy
R&D, Dr. Goldman was responsible for research support for
drug development candidate optimization, drug delivery, formulation,
analytical development and aerosol delivery. With Bayer Pharmaceuticals,
David had responsibility for worldwide product development
as Director of Pharmaceutical Technology in the West Haven
Research Center. Other responsibilities included supporting
new development candidates, characterizing the physical chemical
properties of NMEs, interpreting biopharmaceutic properties
of NMEs and assessing the implications for development. David
also elaborated drug delivery strategies for clinical development,
characterized prospective formulations, developed Phase 1-3
formulations and prepared registration dossiers for U.S. and
International regulatory submissions. After leaving Bayer,
Dr. Goldman founded MedCrystalForms, a company with specialization
in modification of physical forms of NMEs for improved drug
delivery with a focus of development of proprietary technologies
to improve bioavailability of poorly water-soluble drugs. |